DOCSLIB.ORG

Gout Management in Swiss Primary Care – a Retrospective Observational Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gout Management in Swiss Primary Care – a Retrospective Observational Study Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2020 Gout management in Swiss primary care - a retrospective observational study Meier, Rahel ; di Gangi, Stefania ; Valeri, Fabio ; Rosemann, Thomas ; Zechmann, Stefan Abstract: BACKGROUND Gout is the most common form of inflammatory arthritis worldwide and its prevalence is rising. In Switzerland, there are no data available on the characteristics and treat- ment of gout patients. In this study, we aimed to describe numbers of patients affected by gout and hyperuricaemia and unveil approaches Swiss primary care physicians (PCPs) use for the management. METHODS This was a retrospective observational study using electronic medical routine nbsp;data pro- vided from 242 Swiss PCPs. Included were all their patients receiving urate-lowering therapy (ULT), with a diagnostic code for gout or who had a serum uric acid (SUA) measurement. According to their disease status, patients were classified into four subgroups (normal urate, hyperuricaemia, untreated gout, treated gout). For treatment analysis, patients with SUA measurements before and after ULT initiation were in- cluded. Comorbidities and risk factors for secondary causes relevant in the context of gout were collected. Outcomes were prevalence of gout and hyperuricaemia, characteristics of patients according to subgroup, number of SUA measurements, levels of SUA and patients who reached the treatment goal of a SUA level lt;360 micro;mol/l. RESULTS We assessed 15,808 patients and classified them into the subgroups. This yielded a prevalence of 1.0% for gout and 1.2% for hyperuricaemia. 2642 patients were diagnosed with gout of whom 2420 (91.6%) received a ULT. Overall; 41.3% of patients with a gout treatment had at least one SUA measurement; 15.0% of patients with treated gout had a record of SUA measurements before and after ULT initiation; and 57.5% reached the treatment goal of lt;360 micro;mol/l after allopurinol treatment. CONCLUSION Swiss gout patients received comprehensive treatment, which is reflected in a high number of patients treated with ULT, laboratory tests per person and a high treatment success rate, although there is no systematic approach to the treatment of gout. DOI: https://doi.org/10.4414/smw.2020.20209 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-187821 Journal Article Published Version The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License. Originally published at: Meier, Rahel; di Gangi, Stefania; Valeri, Fabio; Rosemann, Thomas; Zechmann, Stefan (2020). Gout man- agement in Swiss primary care - a retrospective observational study. Swiss Medical Weekly, 150:w20209. DOI: https://doi.org/10.4414/smw.2020.20209 2 Original article | Published 24 April 2020 | doi:10.4414/smw.2020.20209 Cite this as: Swiss Med Wkly. 2020;150:w20209 Gout management in Swiss primary care – a retrospective observational study Meier Rahel, Di Gangi Stefania, Valeri Fabio, Rosemann Thomas, Zechmann Stefan, and the FIRE study group Institute of Primary Care, University of Zurich and University Hospital Zurich, Switzerland Summary Introduction BACKGROUND: Gout is the most common form of inflam- Gout is the most common form of inflammatory arthritis matory arthritis worldwide and its prevalence is rising. In worldwide and its prevalence is rising. The highest preva- Switzerland, there are no data available on the charac- lence has been reported in occidental countries and among teristics and treatment of gout patients. In this study, we oceanic populations, affecting up to 7.6% of the popula- aimed to describe numbers of patients affected by gout tion, which is a doubling in occidental countries in the and hyperuricaemia and unveil approaches Swiss primary last 15 years [1–7]. Similar in its clinical appearance to care physicians (PCPs) use for the management. gout, hyperuricaemia is reported to be rising with a report- ed prevalence of up to 21.4% [4–6, 8]. In contrast to gout, METHODS: This was a retrospective observational study which is diagnosed clinically, the diagnosis of hyperuri- using electronic medical routine data provided from 242 caemia is solely defined by serum uric acid (SUA) levels Swiss PCPs. Included were all their patients receiving above 400 µmol/l (6.8 mg/dl) [7, 9–11]. urate-lowering therapy (ULT), with a diagnostic code for gout or who had a serum uric acid (SUA) measurement. There is international evidence that the management of According to their disease status, patients were classified these non-communicable entities varies widely. Previous into four subgroups (normal urate, hyperuricaemia, un- studies investigating primary care populations in different treated gout, treated gout). For treatment analysis, pa- occidental countries reported that 9–74% of all patients di- tients with SUA measurements before and after ULT ini- agnosed with gout had SUA measurements, and 40–84.5% tiation were included. Comorbidities and risk factors for of all patients were treated with urate-lowering therapy secondary causes relevant in the context of gout were col- (ULT) [3, 12–17]. Among treated patients, 21–50% lected. Outcomes were prevalence of gout and hyperuri- reached the treatment target of <360 µmol/l (<6 mg/dl) caemia, characteristics of patients according to subgroup, recommended in most guidelines [18–20]. A recent Swiss number of SUA measurements, levels of SUA and pa- guideline is in concordance with the international guide- tients who reached the treatment goal of a SUA level <360 lines and recommends the treatment target of <360 µmol/ µmol/l. l for gout patients, whereas it is not recommended to treat hyperuricaemia [21]. However, data on prevalence and the RESULTS: We assessed 15,808 patients and classified actual management of gout and hyperuricaemia in primary them into the subgroups. This yielded a prevalence of care is lacking for Switzerland. 1.0% for gout and 1.2% for hyperuricaemia. 2642 patients Therefore, the aims of this study were: were diagnosed with gout of whom 2420 (91.6%) received a ULT. Overall; 41.3% of patients with a gout treatment – To investigate numbers and prevalence of patients af- had at least one SUA measurement; 15.0% of patients fected by gout or hyperuricaemia to describe population with treated gout had a record of SUA measurements be- characteristics and to assess differences in subpopula- fore and after ULT initiation; and 57.5% reached the treat- tions Author contributions RM, SZ and TR developed ment goal of <360 µmol/l after allopurinol treatment. – To describe approaches Swiss primary care physicians the study protocol. FV and CONCLUSION: Swiss gout patients received comprehen- (PCPs) used for the management of gout and to assess SG extracted and analysed if the treatment goal (SUA level ≤ 360 µmol/l) was the data. RM, SZ, SG and sive treatment, which is reflected in a high number of pa- reached and which factors were associated with doing TR wrote the final manu- tients treated with ULT, laboratory tests per person and a script. All authors read, re- high treatment success rate, although there is no system- so. vised and approved the atic approach to the treatment of gout. manuscript. Methods Correspondence: Keywords: gout, hyperuricaemia, urate lowering therapy, Rahel Meier, University of variety of care, electronic medical routine data Study design and setting Zurich, Institute of Primary Care, Pestalozzistrasse 24, We conducted a retrospective observational database CH-8091 Zurich, ra- analysis based on the FIRE (family medicine International hel.meier[at]usz.ch Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 8 Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”. No commercial reuse without permission. See http://emh.ch/en/services/permissions.html. Original article Swiss Med Wkly. 2020;150:w20209 Classification of Primary Care [ICPC] research using elec- Statistical analysis tronic medical records) database, which was established in We described patient level categorical data as numbers 2009 [22]. The FIRE database is a continuous collection and proportions (n, %) and patient level continuous data of structured medical routine data from Swiss primary care as means and standard deviations (SDs). The percentage practices. Until August 2019, more than 540 PCPs (ap- of missing observations was reported when necessary. To proximately 10% of general practitioners working in the compare patient characteristics between patient subgroups, German-speaking region of Switzerland [23]) from more we used the chi-squared test for categorical variables and than 180 practices participated on a voluntary basis. This the analysis of variance (ANOVA) test for continuous vari- resulted in records from more 600,000 patients and more ables. When testing difference in means or proportions be- than 7 million consultations. In brief, the database covers tween two groups, we reported results as 95% confidence patient demographics, vital signs, laboratory data, pre- intervals (CIs). A logistic multivariable mixed model, cor- scribed medication according to anatomical therapeutic recting for sex and repeated measurements (nested random chemical (ATC) coding and diagnoses based on ICPC Ver- effects: PCPs/patients) was used to examine treatment suc- sion 2 [24, 25]. For this analysis, data from 1 January 2009 cess. We specified the model as follows: to 31 August 2018 were included. According to the Local SUA level ≤360 µmol/l ~ fixed effects (X) + random ef- Ethics Committee of the Canton of Zurich, the project did fects of intercept (PCPs/patients) not fall under the scope of the law on human research [26] where X = treatment indicator, sex. and therefore no ethical consent was necessary (BASEC- Nr: Req-2017-00797). We represented the results of the model as odds ratios (ORs) with 95% CI. The observations with missing values Eligibility and inclusion criteria were excluded for regression analysis, but still included in Practices were eligible if they provided SUA measure- the descriptive analysis.
Load more

Recommended publications
  • Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia DINESH KHANNA,1 JOHN D
    Arthritis Care & Research Vol. 64, No. 10, October 2012, pp 1431–1446 DOI 10.1002/acr.21772 © 2012, American College of Rheumatology SPECIAL ARTICLE 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia DINESH KHANNA,1 JOHN D. FITZGERALD,2 PUJA P. KHANNA,1 SANGMEE BAE,2 MANJIT K. SINGH,3 TUHINA NEOGI,4 MICHAEL H. PILLINGER,5 JOAN MERILL,6 SUSAN LEE,7 SHRADDHA PRAKASH,2 MARIAN KALDAS,2 MANEESH GOGIA,2 FERNANDO PEREZ-RUIZ,8 WILL TAYLOR,9 FRE´ DE´ RIC LIOTE´ ,10 HYON CHOI,4 JASVINDER A. SINGH,11 NICOLA DALBETH,12 SANFORD KAPLAN,13 VANDANA NIYYAR,14 DANIELLE JONES,14 STEVEN A. YAROWS,15 BLAKE ROESSLER,1 GAIL KERR,16 CHARLES KING,17 GERALD LEVY,18 DANIEL E. FURST,2 N. LAWRENCE EDWARDS,19 BRIAN MANDELL,20 H. RALPH SCHUMACHER,21 MARK ROBBINS,22 2 7 NEIL WENGER, AND ROBERT TERKELTAUB Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determi- nation regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.
    [Show full text]
  • Colchicine and Probenecid | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Colchicine and Probenecid This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to prevent gouty arthritis. What do I need to tell my doctor BEFORE I take this drug? For all patients taking this drug: If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Blood problems or kidney stones. If you have any of these health problems: Kidney disease or liver disease. If you are pregnant or may be pregnant. Do not take this drug if you are pregnant. If you are taking a salicylate drug like aspirin. If you have liver or kidney problems and you take certain other drugs. Very bad and sometimes deadly side effects have happened in these people. There are many drugs that can do this. Ask your doctor or pharmacist if you are not sure. Children: If the patient is a child younger than 2 years of age. Do not give this drug to a child younger than 2 years of age. Colchicine and Probenecid 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Discontinuation of Urate-Lowering Drugs: a Systematic Review Protocol
    Discontinuation of urate-lowering drugs: a systematic review protocol Virginie Beslon, Perrine Moreau, Annabel Maruani, Hubert Maisonneuve, Bruno Giraudeau, Jean-Pascal Fournier ADMINISTRATIVE INFORMATION Registration PROSPERO registration number: Review team Virginie Beslon, Département de médecine générale, Université de Nantes, France ; [email protected] Perrine Moreau, Département de médecine générale, Université de Nantes, France ; [email protected] Annabel Maruani, Services de dermatologie, CHRU de Tours, Université François Rabelais, Tours, France ; [email protected] Hubert Maisonneuve, Unité des Internistes Généralistes et Pédiatres, Faculté de Médecine, Université de Genève, Suisse ; [email protected] Bruno Giraudeau, INSERM CIC 1415, CHRU de Tours, Université François-Rabelais, Tours, France ; [email protected] Jean-Pascal Fournier, Département de médecine générale, EA 4275-SPHERE, Université de Nantes, France ; [email protected] Contact details Jean-Pascal Fournier (guarantor) Département de médecine générale, Université de Nantes EA 4275-SPHERE, Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Université de Nantes 1 rue, Gaston Veil, 44000, Nantes, France [email protected] Contributions 1. Draft the protocol: VB, PM, AM, HM, BG, JPF 2. Study selection: VB, PM, JPF 3. Extract data from studies: VB, PM, JPF 4. Carry out the analysis: VB, PM, JPF 5. Interpret the analysis: VB, PM, AM, HM, BG, JPF 6. Draft the final review: VB, PM, JPF 7. Critical revision of the review for important intellectual content: VB, PM, AM, HM, BG, JPF Anticipated or actual start date December 30, 2015 Anticipated completion date October 30, 2016 Dissemination plans This paper will be submitted to a leading journal in this field.
    [Show full text]
  • Antihyperuricemics Review 10/25/2010
    Antihyperuricemics Review 10/25/2010 Copyright © 2009 – 2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 10101 Alliance Rd, Ste 201 Cincinnati, Ohio 45242 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. Antihyperuricemics Review FDA-Approved Indications1,2 Drug Manufacturer Indication(s) allopurinol generic - Management of patients with signs and symptoms (Zyloprim® )3 of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
    [Show full text]
  • Febuxostat: a Safe and Effective Therapy for Hyperuricemia and Gout
    DRUG EVALUATION Febuxostat: a safe and effective therapy for hyperuricemia and gout Natasha Jordan† & Febuxostat is a novel, nonpurine, selective xanthine oxidase inhibitor and is a potential Geraldine M McCarthy alternative to allopurinol for patients with hyperuricemia and gout. Unlike allopurinol, which †Author for correspondence undergoes renal elimination, febuxostat is metabolized via hepatic conjugation and Mater Misericordiae oxidation. Phase III studies have shown that febuxostat, at a once-daily dose of 80, 120 or University Hospital, Eccles St. Dublin 7, Ireland 240 mg (safety dose), is more effective than allopurinol (300 mg) in reducing and Tel.: + 35 316 405 514; maintaining serum urate concentrations lower than 6 mg/dl. Reductions in gout flares and [email protected] tophus areas with febuxostat treatment are similar to those occurring with allopurinol therapy. Patients with moderate renal impairment can achieve significant serum urate reductions, without dose adjustments. Therefore, febuxostat represents a viable treatment choice, with documented efficacy and safety in hyperuricemia and gout. Gout is a disease in which tissue deposition of agents) or by decreasing urate synthesis (xan- monosodium urate crystals occurs as a result of thine oxidase inhibitors). These therapeutic hyperuricemia, defined as a serum urate concen- options are not without their limitations. tration that exceeds the limit of solubility (∼6.8 mg/dl [400 µmol/l]). Clinical manifesta- Market overview tions include recurrent attacks of acute inflam- Allopurinol is a competitive inhibitor of xanthine matory arthritis, accumulation of urate crystals oxidase, preventing the oxidation of xanthine to in the form of tophaceous deposits and nephro- uric acid. Allopurinol and its active metabolite, pathy.
    [Show full text]
  • Vinblastine and Sulfinpyrazone Export by the Multidrug Resistance Protein MRP2 Is Associated with Glutathione Export
    British Journal of Cancer (2000) 83(3), 375–383 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1262, available online at http://www.idealibrary.com on Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export R Evers1,4, M de Haas1, R Sparidans2, J Beijnen2, PR Wielinga3, J Lankelma3 and P Borst1 1Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; 3Academic Hospital Vrije Universiteit, Department of Medical Oncology, Room BR232, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 4Present address Georg-Speyer-Haus, Paul Ehrlich straße 42–44, 60596 Frankfurt am, Germany Summary The multidrug resistance proteins MRP1 and MRP2 are members of the same subfamily of ATP-binding cassette transporters. Besides organic molecules conjugated to negatively charged ligands, these proteins also transport cytotoxic drugs for which no negatively charged conjugates are known to exist. In polarized MDCKII cells, MRP1 routes to the lateral plasma membrane, and MRP2 to the apical plasma membrane. In these cells MRP1 transports daunorubicin, and MRP2 vinblastine; both transporters export reduced glutathione (GSH) into the medium. We demonstrate that glutathione transport in MDCKII-MRP1 cells is inhibited by the inhibitors of organic anion transporters sulfinpyrazone, indomethacin, probenecid and benzbromarone. In MDCKII-MRP2 cells, GSH export is stimulated by low concentrations of sulfinpyrazone or indomethacin, whereas export is inhibited down to control levels at high concentrations. We find that unmodified sulfinpyrazone is a substrate for MRP2, also at concentrations where GSH export is inhibited.
    [Show full text]
  • Highly Eribulin-Resistant KBV20C Oral Cancer Cells Can Be Sensitized By
    ANTICANCER RESEARCH 37 : 4139-4146 (2017) doi:10.21873/anticanres.11801 Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose YUJIN PARK*, JI-YEON SON*, BYUNG-MU LEE, HYUNG SIK KIM and SUNGPIL YOON School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea Abstract. Background/Aim: Eribulin mesylate, also called resistant cancer cells can be sensitized with cyclosporine A Halaven ® (HAL), was recently developed as a microtubule- or elacridar, specific P-gp inhibitors that exert their effects targeting drug and is used in the clinic for resistant or at a low dose. These findings provide important information metastatic cancer. Previously, we showed that P-glycoprotein regarding the sensitization of highly HAL-resistant cells with (P-gp)-overexpressing KBV20C oral cancer cells are highly selective P-gp inhibitors and indicate that elacridar may be resistant to HAL compared to sensitive KB cells. This used to treat such highly HAL-resistant cancer cells. qualitative study was designed to identify specific P-gp inhibitors that increase the sensitivity of highly resistant Anti-mitotic drugs, which target different binding sites on cancer cells to HAL. Materials and Methods: In order to tubulin, are widely used for treating different types of cancer identify functional P-gp inhibitors, HAL-treated KBV20C (1, 2). These compounds inhibit mitosis by targeting cells were co-treated with P-gp inhibitors, verapamil, microtubules and preventing their polymerization or elacridar, cyclosporine A, mitotane, piperine, fumagillin, depolymerization (3, 4). Eribulin, also called Halaven ® curcumin, indomethacin, probenecid, sulindac, tesmilifene, (HAL), was recently developed and used in the clinic to treat and C-4.
    [Show full text]
  • 2020 American College of Rheumatology Guideline for the Management of Gout
    Arthritis Care & Research Vol. 0, No. 0, June 2020, pp 1–17 DOI 10.1002/acr.24180 © 2020, American College of Rheumatology ACR GUIDELINE FOR MANAGEMENT OF GOUT 2020 American College of Rheumatology Guideline for the Management of Gout John D. FitzGerald,1 Nicola Dalbeth,2 Ted Mikuls,3 Romina Brignardello-Petersen,4 Gordon Guyatt,4 Aryeh M. Abeles,5 Allan C. Gelber,6 Leslie R. Harrold,7 Dinesh Khanna,8 Charles King,9 Gerald Levy,10 Caryn Libbey,11 David Mount,12 Michael H. Pillinger,5 Ann Rosenthal,13 Jasvinder A. Singh,14 James Edward Sims,15 Benjamin J. Smith,16 Neil S. Wenger,17 Sangmee Sharon Bae,17 Abhijeet Danve,18 Puja P. Khanna,19 Seoyoung C. Kim,20 Aleksander Lenert,21 Samuel Poon,22 Anila Qasim,4 Shiv T. Sehra,23 Tarun Sudhir Kumar Sharma,24 Michael Toprover,5 Marat Turgunbaev,25 Linan Zeng,4 Mary Ann Zhang,20 Amy S. Turner,25 and Tuhina Neogi11 Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommen- dations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of med- ical knowledge, technology, and practice.
    [Show full text]
  • 204820Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204820Orig1s000 SUMMARY REVIEW SUMMARY REVIEW OF REGULATORY ACTION Date: September 26, 2014 From: Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy, and Rheumatology Products, CDER, FDA Subject: Division Director Summary Review NDA Number: 204820 Applicant Name: Hikma Pharmaceuticals, West-Ward Pharmaceuticals (US Agent) Date of Submission: March 28, 2014 (original NDA was submitted on October 5, 2012) PDUFA Goal Date: September 28, 2014 (PDUFA due date for the original NDA was August 5, 2013) Proprietary Name: Mitigare Established Name: Colchicine Dosage form: Capsules Strength: 0.6 mg in each capsule Proposed Indications: Prophylaxis of gout flares in adults and adolescents 16 years of age and older Action: Approval 1. Introduction Hikma Pharmaceuticals through their US agent West-Ward Pharmaceuticals submitted this 505 (b)(2) NDA for use of Mitigare (colchicine) capsules for prophylaxis of gout flares in adults and adolescents 16 years of age and older. The proposed dose is 0.6 mg capsule once or twice daily. The applicant relies on FDA’s finding of safety and effectiveness for the combination product Col-Probenecid (colchicine 0.5 mg and probenecid 500 mg, ANDA 84729) and published literature to support its colchicine product. In addition, the applicant conducted clinical pharmacology studies: a relative bioavailability study to support reliance on FDA’s finding of safety and effectiveness for Col-Probenecid; a food effect study; and drug-drug interaction studies to support relevant dose modification recommendations for its product when used with some other drugs. The proposed regulatory pathway and the submitted clinical pharmacology data to support this application are reasonable.
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]
  • Evidence for a Postsecretory Reabsorptive Site for Uric Acid in Man
    Evidence for a Postsecretory Reabsorptive Site for Uric Acid in Man Herbert S. Diamond, James S. Paolino J Clin Invest. 1973;52(6):1491-1499. https://doi.org/10.1172/JCI107323. Research Article The effects of administration of drug combinations on uric acid excretion were studied in order to test the hypothesis that a portion of renal tubular reabsorption of uric acid occurs distal to the uric acid secretory site. Oral administration of pyrazinamide (3 g) during probenecid uricosuria (probenecid 500 mg every 6 h) decreased urate excretion from 463 μg/min following probenecid medication alone to 135 μg/min following probenecid plus pyrazinamide (P < 0.01). When a greater uricosuric effect was induced with a 2 g oral dose of probenecid, the decrement in urate excretion which followed pyrazinamide administration (3 g) was more pronounced (2,528 μg/min following probenecid alone, 574 μg/min following probenecid plus pyrazinamide). Results were similar when an 800 mg oral dose of sulfinpyrazone was given in place of probenecid (1,885 μg/min following sulfinpyrazone alone, 475 μg/min following sulfinpyrazone plus pyrazinamide). Thus, apparent urate secretion (measured as the decrease in excretion of urinary uric acid resulting from pyrazinamide administration) appeared to vary, depending upon the degree of inhibition of reabsorption produced by probenecid or sulfinpyrazone. When small doses of aspirin were administered in place of pyrazinamide to produce secretory inhibition, the results were similar. Neither probenecid nor pyrazinamide significantly altered urate excretion when administered to patients with serum salicylate levels above 14 mg/100 ml. These results are interpreted as suggesting that […] Find the latest version: https://jci.me/107323/pdf Evidence for a Postsecretory Reabsorptive Site for Uric Acid in Man HERBERT S.
    [Show full text]